$2.040
+0.041 (+2.00%)終値時点
RGNT の同業比較
In the context of the broader market, RGNT competes directly with industry leaders such as INTS and BNGO. With a market capitalization of $14.05M, it holds a significant position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against INTS's N/A and BNGO's 52.80%. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.
Regentis Biomaterials Ltd の財務パフォーマンス
Regentis Biomaterials has shown a significant turnaround in its financials, with total equity projected to turn positive at $4,744,000 by Q4 2025, compared to negative equity in previous quarters. This indicates improving financial health and potential for growth.
Financials
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。